Skip to main content

Medication

Latest
u.s. business
Johnson & Johnson facing insurance fraud charges in New York over opioid claims
british columbia
B.C. moves to dramatically increase access to safe alternatives to illicit drugs
u.s. business
Eli Lilly says its antibody reduces need for hospitalization in moderate COVID-19 patients
Subscriber content
u.s. business
Bayer settles thousands of U.S. Roundup cases with trial attorneys
Subscriber content
opinion
Canada’s vaccine legacy: Influenza, polio and COVID-19
Christopher Rutty
u.s. business
Eli Lilly says its arthritis drug helps accelerate recovery in COVID-19 patients treated with remdesivir
Subscriber content

More Stories Below Advertisement

international business
Gilead to buy cancer drug maker Immunomedics for $21-billion
Subscriber content
european business
Bayer extends contract of CEO Werner Baumann as company makes progress on Roundup settlement
Subscriber content
european business
Curevac gets $300-million grant to hurry up COVID-19 vaccine
Subscriber content
u.s. business
Pfizer sees COVID-19 vaccine data in thick of U.S. election fight
Subscriber content
european business
EU pays €336-million to secure AstraZeneca’s potential COVID-19 vaccine
u.s. business
U.S. to charge Teva with conspiring to raise prices of generic drugs, sources say
Subscriber content
asia-pacific business
Takeda to sell Japan consumer health unit valued at $2.3-billion to Blackstone
u.s. business
Novartis CEO says COVID-19 makes valuing takeover targets tougher
Subscriber content
european business
Bayer to pay $1.6-billion to resolve U.S. claims over Essure birth-control device
u.s. business
Johnson & Johnson to test potential coronavirus vaccine in up to 60,000 volunteers
Subscriber content

More Stories Below Advertisement

u.s. business
Johnson & Johnson buying Momenta Pharmaceuticals for around $6.5-billion
Subscriber content
u.s. business
U.S. states reportedly seeking $26.4-billion from drug firms in opioid litigation
international business
Sanofi snags another U.S. biotech firm with $3.7-billion Principia deal
Subscriber content
international business
CureVac shares surge 222% in vaccine developer’s Nasdaq debut
report on business
Shoppers Drug Mart to test three medical clinics in Toronto area this year
Subscriber content
u.s. business
Pfizer signs deal to manufacture Gilead’s remdesivir for COVID-19
european business
AstraZeneca signs its first COVID-19 vaccine deal with a Chinese company
report on business
Bausch to pay $94-million plus costs to resolve Canadian securities class action
u.s. business
U.S. pursues nearly $13-billion of claims in Purdue Pharma opioid probes, sources say
u.s. business
Questions being raised after Kodak’s stock has a big moment
international business
Kodak’s lucrative deal with U.S. government and subsequent stock surge prompt questions from SEC: report
Subscriber content
european business
Bayer tumbles to $11.2-billion quarterly net loss after litigation charges
advisor mutual funds
Active management finds niche in post-pandemic market
Globe Advisor content
report on business
Years after Valeant scandal, SEC unveils charges against firm, former executives
Subscriber content
international business
AstraZeneca to be exempt from coronavirus-vaccine liability claims in most countries
u.s. business
J&J starts human safety trial for its COVID-19 vaccine candidate
canada
Health Canada approves remdesivir to treat patients with severe COVID-19 symptoms
u.s. business
Pfizer says other developed countries will get same price as U.S. for COVID-19 vaccine
Subscriber content
report on business
Vancouver COVID-19 therapy developer AbCellera eyeing potential IPO as early as fall
Subscriber content
european business
German COVID-19 vaccine developer CureVac files for U.S. IPO
Subscriber content
To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies